Advertisement

Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice

      Highlights

      • New drugs have proved to further improve long-term outcomes in patients with HFrEF.
      • A proposal for combing these new drugs in clinical practice is provided.
      • Frequent clinical evaluation in the first phases of disease is advisable to attain optimal therapy.

      Abstract

      Pharmacological approach to heart failure with reduced ejection fraction (HFrEF) is evolving, as recently published large randomized clinical trials have implemented the disposal of HFrEF treatments with four new classes of drugs, namely angiotensin receptor/neprilysin inhibitor , sodium-glucose co-transporters 2 inhibitors , soluble guanylate cyclase modulators and myosin activators, which have proved to further improve patients’ quality of life and long-term outcomes. As these novel drugs target additional pathways not already intercepted by the guideline-directed medical therapy, integration of them in the management of HFrEF is desirable. This review paper aims to provide an overview of the current evolving concepts of HFrEF therapy joining the most recent evidences and to furnish practical suggestions for the use of these new classes of drugs in clinical practice
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ponikowski P
        • Voors AA
        • Anker SD
        • Bueno H
        • Cleland JGF
        • Coats AJS
        • et al.
        ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016 Jul 14; 37: 2129-2200
        • McMurray JJV
        • Packer M.
        How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine.
        Circulation. 2020 Dec 30; (CIRCULATIONAHA.120.052926)
        • Maddox TM
        • Januzzi JL
        • Allen LA
        • Breathett K
        • Butler J
        • Davis LL
        • et al.
        Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.
        J Am Coll Cardiol. 2021; (S0735109720378670)
        • McMurray JJV
        • Packer M
        • Desai AS
        • Gong J
        • Lefkowitz MP
        • Rizkala AR
        • et al.
        Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure.
        N Engl J Med. 2014 Sep 11; 371: 993-1004
        • Januzzi JL
        • Prescott MF
        • Butler J
        • Felker GM
        • Maisel AS
        • McCague K
        • et al.
        Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
        JAMA. 2019 Sep 17; 322: 1085
        • Sidhu K
        • Sanjanwala R
        • Zieroth S.
        Hyperkalemia in heart failure.
        Curr Opin Cardiol. 2020; 35: 150-155
        • Velazquez EJ
        • Morrow DA
        • DeVore AD
        • Duffy CI
        • Ambrosy AP
        • McCague K
        • et al.
        Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure.
        N Engl J Med. 2019; 380: 539-548
        • Wachter R
        • Senni M
        • Belohlavek J
        • Straburzynska-Migaj E
        • Witte KK
        • Kobalava Z
        • et al.
        Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
        Eur J Heart Fail. 2019; 21: 998-1007
        • Senni M
        • McMurray JJV
        • Wachter R
        • McIntyre HF
        • Anand IS
        • Duino V
        • et al.
        Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study: Safety of sacubitril/valsartan in HFrEF.
        Eur J Heart Fail. 2018; 20: 491-500
        • Rohde LE
        • Chatterjee NA
        • Vaduganathan M
        • Claggett B
        • Packer M
        • Desai AS
        • et al.
        Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause.
        JACC Heart Fail. 2020; 8: 844-855
        • McMurray JJV
        • Solomon SD
        • Inzucchi SE
        • Køber L
        • Kosiborod MN
        • Martinez FA
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Packer M
        • Anker SD
        • Butler J
        • Filippatos G
        • Pocock SJ
        • Carson P
        • et al.
        Cardiovascular and renal outcomes with empagliflozin in heart failure.
        N Engl J Med. 2020; 383: 1413-1424
        • Lopaschuk GD
        • Verma S.
        Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors.
        JACC Basic Transl Sci. 2020; 5: 632-644
        • Joshi SS
        • Singh T
        • Newby DE
        • Singh J.
        Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
        Heart. 2021; (heartjnl-2020-318060)
        • Dutka M
        • Bobiński R
        • Ulman-Włodarz I
        • Hajduga M
        • Bujok J
        • Pająk C
        • et al.
        Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure.
        Heart Fail Rev. 2021; 26: 603-622
        • US Food and Drug Administration
        FDA approves new treatment for a type of heart failure.
        FDA, 2020 ([Internet] Available from:)
        • Zannad F
        • Ferreira JP
        • Pocock SJ
        • Anker SD
        • Butler J
        • Filippatos G
        • et al.
        SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
        The Lancet. 2020; 396: 819-829
        • Verma S
        • McGuire DK
        • Kosiborod MN.
        Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
        Circulation. 2020; 142: 2201-2204
        • Docherty KF
        • Jhund PS
        • Inzucchi SE
        • Køber L
        • Kosiborod MN
        • Martinez FA
        • et al.
        Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
        Eur Heart J. 2020; 41: 2379-2392
        • Vaduganathan M
        • Claggett BL
        • Jhund PS
        • Cunningham JW
        • Pedro Ferreira J
        • Zannad F
        • et al.
        Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
        The Lancet. 2020; 396: 121-128
        • Bhatt DL
        • Szarek M
        • Steg PG
        • Cannon CP
        • Leiter LA
        • McGuire DK
        • et al.
        Sotagliflozin in patients with diabetes and recent worsening heart failure.
        N Engl J Med. 2021; 384: 117-128
        • Rosano G
        • Quek D
        • Martínez F.
        Sodium–Glucose Co-transporter 2 inhibitors in heart failure: recent data and implications for practice.
        Card Fail Rev. 2020; 6: e31
        • Armstrong PW
        • Pieske B
        • Anstrom KJ
        • Ezekowitz J
        • Hernandez AF
        • Butler J
        • et al.
        Vericiguat in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2020; 382: 1883-1893
        • Psotka MA
        • Gottlieb SS
        • Francis GS
        • Allen LA
        • Teerlink JR
        • Adams KF
        • et al.
        Cardiac calcitropes, myotropes, and mitotropes.
        J Am Coll Cardiol. 2019; 73: 2345-2353
        • Teerlink JR
        • Diaz R
        • Felker GM
        • McMurray JJV
        • Metra M
        • Solomon SD
        • et al.
        Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
        N Engl J Med. 2021; 384: 105-116
        • Butler J
        • Anstrom KJ
        • Armstrong PW
        • For the VICTORIA Study Group
        Comparing the benefit of novel therapies across clinical trials: insights from the victoria trial.
        Circulation. 2020; 142: 717-719
        • Lam PH
        • Dooley DJ
        • Fonarow GC
        • Butler J
        • Bhatt DL
        • Filippatos GS
        • et al.
        Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial: Below-target vs. target doses of enalapril and outcomes in heart failure.
        Eur J Heart Fail. 2018; 20: 359-369
        • Vardeny O
        • Claggett B
        • Packer M
        • Zile MR
        • Rouleau J
        • Swedberg K
        • et al.
        Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
        Eur J Heart Fail. 2016; 18: 1228-1234
        • Margonato D
        • Galati G
        • Mazzetti S
        • Cannistraci R
        • Perseghin G
        • Margonato A
        • et al.
        Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
        Heart Fail Rev. 2021; 26: 337-345